Absci Corporation ABSI is scheduled to report first-quarter 2024 results on May 14. Let's see how things might have shaped up prior to the announcement. Absci is a data-first generative AI drug ...

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.

ABSI's Financials Remain Weak, Though Liquidity Has Improved. Absci reported a full-year 2024 revenue of $4.5 million. That was down from $5.7 million in 2023.

Absci Corp ABSI shares are trading lower by 9.4% to $4.46 Wednesday afternoon after the company announced an offering of 16.7 million shares at $4.50 per share.. The underwriters have an option to ...

Absci Corporation ABSI announced that it has entered into a collaboration agreement with pharma goliath, AstraZeneca AZN, to deliver an artificial intelligence (AI)-designed antibody for an ...